Future research might address whether copeptin may distinguish between certain epileptic syndromes or whether the magnitude of copeptin increase is related to clinical outcomes, namely the recurrence of FS and the risk to develop epilepsy. This evidence concerns the gene AVP and epilepsy syndrome.